NEWS | BEAM Alliance


Pherecydes Pharma and BIOASTER join forces to explore the use of phage therapy to treat complicated urinary tract infections

Romainville and Lyon, France, July 16, 2019 – Pherecydes Pharma and BIOASTER, the French Technology Research Institute (TRI) for Microbiology and Infectious Diseases, announce the signing of a
collaboration agreement.

This project, called PhagUTI, is a unique opportunity for the partners to capitalize on BIOASTER’s unique expertise in pre-clinical models and the extensive experience of Pherecydes in the selection, characterization and production of bacteriophages.

Full PR available here